Context Therapeutics has received FDA approval for its IND application, initiating a Phase 1 clinical trial of CTIM-76.

Loncastuximab tesirine, marketed under the brand name Zynlonta, is a targeted antibody-drug conjugate (ADC) developed by ADC Therapeutics SA.

Remix Therapeutics has started dosing the first participants in a pair of Phase 1 studies. These trials are testing REM-422 in treating Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS).

JSKN003 is a novel ADC targeting two distinct epitopes of HER2, independently developed by Alphamab Biopharmaceuticals utilizing its proprietary glycan-based site-specific conjugation platform.

Alpha-9 Oncology reports initial dosing of the first participant in a phase 1 trial for A9-3202, targeting locally advanced or metastatic melanoma patients.

Inebilizumab-cdon, commercially known as Uplinza, is an innovative immunomodulatory agent developed by Viela Bio, now a part of Horizon Therapeutics USA.

Atsena Therapeutics Reveals Encouraging Results from Initial Group in Phase 1/2 Study of ATSN-201 Gene Treatment for X-linked Retinoschisis (XLRS).

Medilink Therapeutics will present preliminary results from the first human clinical Phase 1 trial of YL202 for the treatment of locally advanced or metastatic non-small cell lung cancer and breast cancer (NCT05653752).

EyeDNA Therapeutics Reveals Encouraging Two-Year Results at ARVO for its Phase 1/2 Study on HORA-PDE6b Genetic Treatment in Retinitis Pigmentosa Patients with Dual Mutations in PDE6b.

Tisagenlecleucel, marketed under the brand name Kymriah, is a pioneering immunotherapy medication developed by Novartis.

RemeGen Showcases 16 New Clinical Studies on ADCs Disitamab Vedotin and RC88 Targeting Multiple Cancer Types at Conference.

Lisocabtagene maraleucel, marketed under the brand name Breyanzi, is a revolutionary immunotherapy medication developed by Bristol-Myers Squibb.